Savara (SVRA) Stock Holds Near $4.92 After -7.5% Pullback With FDA Decision Ahead
Key Takeaways
- Savara (SVRA) trades near $4.92, down roughly 7.5% over the trailing 30 days, within a 52-week range of $3.35 to $7.01.
- The company's lead candidate, MOLBREEVI (molgramostim), has a U.S. FDA PDUFA target action date of November 22, 2026.
- Positive Phase 3 IMPALA-2 data continue to anchor the regulatory package, supplemented by biomarker and exercise-capacity data presented during 2026.
- Wall Street consensus remains "Strong Buy," with an average price target near $11, well above the recent share price.
- Savara remains pre-revenue and cash-consuming, reporting a $40.2 million net loss in Q2 2026 with roughly $173 million in cash at mid-year.
Where SVRA Stands in the Current Market
SVRA shares have settled into a lower trading range in recent weeks after a modest pullback. The stock has drifted from roughly $5.32 about a month ago to approximately $4.92, a decline of about 7.5% over the trailing 30 days. The company's market capitalization stands near $1.25 billion, and the stock carries a low beta of about 0.20, indicating that it has historically traded with less day-to-day volatility than the broader market. Investor attention remains concentrated on the upcoming regulatory milestones rather than short-term price swings, a pattern common among clinical-stage biopharmaceutical companies whose valuations hinge on binary approval events. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Savara's Business Focus and Competitive Position
Savara Inc. is a clinical-stage biopharmaceutical company focused exclusively on rare respiratory diseases. Its lead program, MOLBREEVI (molgramostim inhalation solution), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) delivered via an investigational eFlow nebulizer system. The therapy is being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease in which surfactant accumulates in the alveoli and impairs gas exchange. There is currently no approved pharmacologic treatment for aPAP in most of the world, leaving whole lung lavage as the standard of care. MOLBREEVI has received Fast Track and Breakthrough Therapy designations from the FDA, Orphan Drug Designation from both the FDA and EMA, and Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA. This regulatory profile, combined with a first-to-market opportunity in an underserved indication, is why investors follow the stock closely. From what I see, these designations strengthen the case for potential approval.
Recent Developments Shaping the SVRA Narrative
Several verified developments have shaped Savara's narrative over the past 30 days. The most consequential remains the company's U.S. Biologics License Application (BLA), which is under Priority Review with a PDUFA target action date of November 22, 2026. In parallel, a Marketing Authorization Application is under review by the EMA, with a decision expected in Q1 2027, and by the UK's MHRA, with a decision expected in Q4 2026. On the clinical front, Savara presented new Phase 3 IMPALA-2 data during 2026, including exercise-capacity results and biomarker analyses showing that molgramostim improved pulmonary gas transfer and reduced disease-related biomarkers. The company also announced European and Australian patent grants for the MOLBREEVI liquid formulation, extending protection to March 2041. Financially, Savara reported a second-quarter 2026 net loss of $40.2 million, or $(0.16) per share, wider than the prior-year period, reflecting investments in commercial infrastructure ahead of a potential launch. The company held approximately $173 million in cash and short-term investments as of June 30, 2026, with access to up to roughly $150 million in additional non-dilutive capital upon FDA approval. Analyst activity has been supportive: JPMorgan initiated coverage with an Overweight rating and a $12 price target in early October 2026. I reviewed recent filings and signals through Tickeron’s AI Daily Buy/Sell Signals to stay updated on momentum.
2026 Outlook and Key Items to Monitor
The central catalyst for Savara is the FDA's decision on MOLBREEVI, expected on or before November 22, 2026. A U.S. approval would mark the company's transition from a clinical-stage developer toward a commercial-stage rare disease business, while the EMA and MHRA decisions expected in late 2026 and early 2027 could expand the addressable opportunity in Europe and the UK. Investors should also monitor commercial launch readiness, including the build-out of the market development and field teams, as well as the company's cash position and any future financing or dilution. Ongoing disclosures from the IMPALA-2 open-label period, analyst rating updates, and the pace of regulatory review remain important sentiment drivers. As with any pre-revenue biotech, the outlook depends heavily on regulatory outcomes and successful commercial execution, and the shares may remain sensitive to news flow around these milestones. I'm watching this closely as the date nears.
Exploring AI Tools for Biotech Research
In my own workflow, I frequently turn to Tickeron’s Trending AI Robots to scan for relevant signals across the market. The platform highlights top-performing bots with different strategies and timeframes, which helps surface active, high-conviction ideas without sifting through everything manually. It serves as a practical complement when evaluating names like SVRA alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SVRA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for SVRA moved below the 200-day moving average on September 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SVRA as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for SVRA turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for SVRA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SVRA's RSI Indicator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where SVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +1.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where SVRA advanced for three days, in 191 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. SVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.252) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pharmaceuticals developer
Industry Biotechnology
Advertisement